Anthrax vaccine: Increasing intervals between the first two doses enhances antibody response in humans

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 213-216

  Pittman, Phillip R ^a   Mangiafico, Joseph A ^a   Rossi, Cynthia A ^a   Cannon, Timothy L ^b   Gibbs, Paul H ^a   Parker, Gerald W ^a   Friedlander, Arthur M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b US Army Med Info Syst Serv A ^*  (United States)

Author keywords

Anthrax vaccine; Protective antigen ELISA titers

Indexed keywords

ANTHRAX VACCINE; BACTERIUM ANTIBODY; IMMUNOGLOBULIN G ANTIBODY;

ANTHRAX; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; HUMAN; IMMUNOPROPHYLAXIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROCONVERSION; SERODIAGNOSIS; VACCINATION;

EID: 0034666734     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00174-2     Document Type: Article

References (11)

1. Anthrax vaccine adsorbed [package insert]. Lansing, Michigan, Department of Public Health; 1978.
2. Wright G.G., Green T.W., Kanode R.G. Jr. Studies of Immunity in Anthrax. V. Immunizing activity of alum-precipitated protective antigen. J. Immunol. 73:1954;387-391.
3. Brachman P.S., Herman G., Plotkin S.A., Fekety R., Werrin M., Ingraham N.R. Field evaluation of a human anthrax vaccine. Am. J. Pub. Hlth. 52:1962;632-645.
4. Wright G.G., Puziss M., Neely W.B. Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. J. Bacteriol. 83:1962;515-522.
5. Puziss M., Wright G.G. Studies on immunity in anthrax. X. Gel-Adsorbed protective antigen for immunization of man. J. Bacteriol. 85:1963;230-236.
6. Puziss M., Manning L.C., Lynch J.W., Barclay E., Abelow I., Wright G.G. Large-scale production protective antigen of Bacillus anthracis in anaerobic cultures. Appl. Microbiol. 11:1963;330-334.
7. Pittman P.R., Makuch R.S., Mangiafico J., Cannon T.L., Gibbs P.H., Peters C.J. Long-term duration of detectable neutralizing antibodies after administration of live-attenuated VEE vaccine and following booster vaccination with inactivated VEE vaccine. Vaccine. 14:1996;337-343.
8. Pittman P.R., Liu C.T., Cannon T., Makuch R.S., Mangiafico J.A., Gibbs P.H., Peters C.J. Safety and immunogenicity of an inactivated Rift Valley fever vaccine in humans over a 12-year period. Vaccine. 18:1999;181-189.
9. Iacono-Connors L.C., Novak J., Rossi C., Mangiafico J., Ksiazek T. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Clin. Diag. Lab. Immunol. 1:1994;78-82.
10. Iacono-Connors L.C., Welkos S.L., Ivins B.E., Dalrymple J.M. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1991;1961-1965.
11. StatXact Turbo User Manual, "Statistical Software for Exact Non-parametric Inference," Cytel Corp., 1992. pp. 547-554.